Sodium alginate as a novel therapeutic option in experimental colitis

Scandinavian Journal of Immunology

Volumn 61, Issue 4, 2005, Pages 316-321

  Mirshafiey, A ^a   Khodadadi, A ^a   Rehm, B H ^b   Khorramizadeh, M R ^a   Eslami, M B ^a   Razavi, A ^a   Saadat, F ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ALGINIC ACID; CYTOKINE; GELATINASE A; ICOSANOID; INTERLEUKIN 6; LEUKOTRIENE B4; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL MODEL; FEMALE; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; RAT; SCORING SYSTEM; ULCERATIVE COLITIS; ZYMOGRAPHY;

ALGINATES; ANIMALS; CELL LINE, TUMOR; COLITIS, ULCERATIVE; DINOPROSTONE; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GLUCURONIC ACID; HEXURONIC ACIDS; HISTOCYTOCHEMISTRY; HUMANS; INTERLEUKIN-6; INTESTINAL MUCOSA; LEUKOTRIENE B4; MATRIX METALLOPROTEINASE 2; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 18344396767     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2005.01571.x     Document Type: Article

References (35)

1. Qiu BS, Pfeiffer CJ, Keith JC. Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Dig Dis Sci 1996;41:1625-30.
2. Dobosz M, Mionskowska L, Dobrowolski S et al. Is nitric oxide and heparin treatment justified in inflammatory bowel disease? An experimental study. Scand J Clin Lab Invest 1996;56:657-63.
3. Hanauer S. Medical therapy of ulcerative colitis. Lancet 1993;342:412-7.
4. Skjak-Braek G, Grasdalen H, Larson B. Monomer sequence and acetylation pattern in some bacterial alginates. Carbohydr Res 1986;15:239-50.
5. Bucke C. Cell immobilization in calcium alginate. In: Colowick NP, Kaplan NP, Mosbach K, eds. Immobilized Enzyme and Cells, Part B: Methods in Enzymology. New York Academic Press, 1987:175-88.
6. Rehm BH. Alginate lyase from Pseudomonas aeruginosa CF1/M1 prefers the hexameric oligomannuronate as substrate. FEMS Microbiol Lett 1998;165:175-80.
7. Rehm BH, Valla S. Bacterial alginates: biosynthesis and applications. Appl Microbiol Biotechnol 1997;48:281-8.
8. Odell EW, Oades P, Lombardi T. Symptomatic foreign body reaction to haemostatic alginate. Br J Oral Maxillofac Surg 1994;31:165-9.
9. Lanza RP, Kuhtreiber WM, Ecker DM, Marsh JP, Chick WL. Transplantation of porcine and bovine islets into mice without immunosuppression using uncoated alginate microspheres. Transplant Proc 1995;27:3321.
10. Lee JH, Kim WG, Kim SS, Lee JH, Lee HB. Development and characterization of an alginate-impregnated polyester vascular graft. J Biomed Mater Res 1997;36:200-8.
11. Kuipers ME, Heegsma J, Bakker HI et al. Design and fungicidal activity of mucoadhesive lactoferrin tablets for the treatment of oropharyngeal candidosis. Drug Deliv 2002;9:31-8.
12. Streitenberger SA, Villaverde MJ, Sanchez-Ferrer A, Garcia-Carmona F. Microencapsulation of Aerococcus viridans with catalase and its application for the synthesis of dihydroxyacetone phosphate. Appl Microbiol Biotechnol 2002;58:73-6.
13. Efentakis M, Buckton G. The effect of erosion and swelling on the dissolution of theophylline from low and high viscosity sodium alginate matrices. Pharm Dev Technol 2002;7:69-77.
14. Asada M, Sugie M, Inoue M et al. Inhibitory effect of alginic acids on hyaluronidase and on histamine release from mast cells. Biosci Biotechnol Biochem 1997;61:1030-2.
15. Hasegawa T, Takahashi T, Inada Y, Yamada C, Tanaka Y. Reparative effects of sodium alginate (Alloid G) on radiation stomatitis. Nippon Igaku Hoshasen Gakkai Zasshi 1989;25:1047-51.
16. Oshitani T, Okada K, Kushima T et al. Clinical evaluation of sodium alginate on oral mucositis associated with radiotherapy. Nippon Gan Chiryo Gakkai Shi 1990;20:1129-34.
17. Gong YF, Huang ZJ, Qiang MY et al. Suppression of radioactive strontium absorption by sodium alginate in animals and human subjects. Biomed Environ Sci 1991;4:237-82.
18. Yamada T, Marshall S, Specian RD, Grisham MB. A comparative analysis of two models of colitis in rats. Gastroenterology 1991;102:1524-34.
19. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989;96:795-803.
20. Videla S, Garcia-Lafuente A, Antolin M et al. Antitumor necrosis factor therapy in rat chronic granulomatous colitis: critical dose-timing effects on outcome. J Pharmacol Exp Ther 1998;287: 854-9.
21. Wallace JL, MacNaughton WK, Morris GP, Beck PL. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 1989;96:29-36.
22. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activator in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980;102:196-202.
23. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205.
24. Gasche C, Reinisch W, Lochs H, Gangl A. Interleukin-6 production in Crohn's disease. Gastroenterology 1992;103:1120-1.
25. Gross V, Andus T, Caesar I, Roth M, Scholmerich J. Evidence for continuous stimulation of interleukin 6 production in Crohn's disease. Gastroenterology 1992;102:514-9.
26. Braegger CP, Nicholis S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;329:89-91.
27. Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984;86:453-60.
28. Raithel M, Matek M, Baenkler HW, Jorde W, Hahn EG. Mucosal histamine content and histamine secretion in Crohn's disease, ulcerative colitis and allergic enteropathy. Int Arch Allergy Immunol 1995;108:127-33.
29. Fox CC, Lazenby AJ, Moore WC, Yardley JH, Bayless TM, Lichtenstein LM. Enhancement of human intestinal mast cell mediator release in active ulcerative colitis. Gastroenterology 1990;99:119-24.
30. Winterkamp S, Weidenhiller M, Otte P et al. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease. Am J Gastroenterol 2002;97:3071-7.
31. Heller W, Durst J, Stockeler R. Value of beta glucuronidase and hyaluronidase determination in Crohn's disease and ulcerative colitis. Med Welt 1979;30:1472-7.
32. Van der Wiel-Korslanje JA, Winkler KC. The faecal flora in ulcerative colitis. J Med Microbiol 1975;8:491-501.
33. Pirila E, Ramamurthy NS, Sorsa T, Salo T, Hietanen J, Maisi P. Gelatinase A (MMP-2), collagenase-2 (MMP-8), and laminin-5 gamma2-chain expression in murine inflammatory bowel disease (ulcerative colitis). Dig Dis Sci 2003;48:93-8.
34. von Lampe B, Barthel B, Coupland SE, Riecken EO, Rosewicz S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000;47:63-73.
35. Agren MS. Four alginate dressings in the treatment of partial thickness wounds: a comparative experimental study. Br J Plast Surg 1996;49:129-34.